All In Biotech

Drug Trial Radar · NCT06487559

A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)

A Phase 1b Study to Evaluate the Safety and Pharmacokinetics of Livmoniplimab in Combination With Budigalimab in Chinese Subjects With Locally Advanced or Metastatic Child-Pugh A Hepatocellular Carcinoma Who Have Progressed After a First-Line Regimen That Includes an Immune Checkpoint Inhibitor

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

3

Actual

Start

Sep 11, 2024

Primary completion

Sep 18, 2026

Study completion Sep 18, 2026

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Jul 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presenting with HCC have advanced unresectable or metastatic disease. The purpose of this study is to assess adverse events and how livmoniplimab in combination with budigalimab moves through the body in adult Chinese participants with Locally Advanced or metastatic Child-Pugh A Hepatocellular Carcinoma (HCC). Livmoniplimab is an investigational drug being developed for the treatment of HCC. There are 2 stages to this study. Stage 1 is a safety run-in. There are 2 treatment arms in stage 1 and participants will receive escalating doses of Livmoniplimab in combination with budigalimab (fixed dose). Stage 2 is dose expansion. There are 2 treatment arms in stage 2 and participants will receive Livmoniplimab in combination with budigalimab in multiple doses. Approximately 20 adult participants will be enrolled in the study across 15 sites in China. In part 1 (dose escalation), participants will be intravenously infused with escalating doses of livmoniplimab in combination with budigalimab every 3 weeks. In part 2 (dose expansion), participants will be intravenously infused with livmoniplimab in combination with budigalimab in multiple doses every 3 weeks. The estimated duration of the study is up to 2 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.

Conditions

  • Hepatocellular Carcinoma (HCC)

Interventions

  • LivmoniplimabDrug

    Intravenous infusion

  • BudigalimabDrug

    Intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Adverse Events (AE)Time frame: Up to Approximately 2 Years
  2. Number of Participants with Dose-Limiting Toxicities (DLT)Time frame: Up to Approximately 2 Years
  3. Maximum Plasma Concentration (Cmax) of Livmoniplimab and BudigalimabTime frame: Up to Approximately 2 Years
  4. Area Under the Serum Concentration Versus Time Curve (AUC) of Livmoniplimab and BudigalimabTime frame: Up to Approximately 2 Years

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Youan Hospital, Capital Medical University -No differernce with previous /ID# 261928

    Beijing, Beijing Municipality, China

  • Mengchao Hepatobiliary Hospital of Fujian Medical University /ID# 262443

    Fuzhou, Fujian, China

  • Sun Yat-Sen University Cancer Center /ID# 262092

    Guangzhou, Guangdong, China

  • Nanfang Hospital of Southern Medical University /ID# 262091

    Guangzhou, Guangdong, China

  • Harbin Medical University Cancer Hospital /Id# 262070

    Harbin, Heilongjiang, China

  • Henan Cancer Hospital /ID# 262098

    Zhengzhou, Henan, China

  • Hubei Cancer Hospital /ID# 262030

    Wuhan, Hubei, China

  • The Second Affiliated Hospital of Nanchang University /ID# 262085

    Nanchang, Jiangxi, China

  • Liaoning Cancer Hospital & Institute /ID# 268023

    Shenyang, Liaoning, China

  • Zhongshan Hospital Fudan University /ID# 262135

    Shanghai, Shanghai Municipality, China

  • Zhejiang Cancer hospital /ID# 262046

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.